Fed’s Powell opens door to potential rate cuts at Jackson Hole
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company with a market capitalization of $240 million, recently reported that its Chief Scientific Officer, Carter Todd Alfred, sold 5,413 shares of common stock on February 11, 2025. The shares were sold at an average price of $4.45, totaling approximately $24,087. Following this transaction, Alfred holds 81,023 shares in the company. This sale was conducted under an automatic instruction letter to cover tax obligations related to the vesting of restricted stock units, and not as a discretionary trade by Alfred. The stock, which has fallen about 26% in the past week, is currently showing oversold conditions according to InvestingPro technical indicators. With the stock trading significantly below its 52-week high of $10.66, InvestingPro’s Fair Value analysis suggests the stock may be undervalued at current levels.
In other recent news, Voyager Therapeutics, a biotechnology firm specializing in neurogenetic medicines, announced a shift in its gene therapy program for amyotrophic lateral sclerosis (ALS). The company will explore alternative payloads for its development candidate VY9323 following indications from non-human primate studies that the current payload did not meet desired standards. This development has led to a delay in the investigational new drug (IND) application for VY9323, initially slated for mid-2025. Despite this, Voyager’s other gene therapy programs remain unaffected, with IND filings expected in 2025 for gene therapies targeting GBA1 Parkinson’s and other GBA1-mediated diseases, as well as Friedreich’s ataxia. An IND filing for VY1706 is anticipated in 2026.
The company’s decision to reassess the VY9323 program does not affect its collaborations with Neurocrine (NASDAQ:NBIX) Biosciences. Furthermore, H.C. Wainwright confirmed a Buy rating for Voyager Therapeutics, expressing optimism about the company’s upcoming studies and data releases. Citi also issued a Buy rating for Voyager, highlighting the firm’s innovative approach to gene therapy for central nervous system disorders.
These recent developments in Voyager Therapeutics’ ALS gene therapy program and the continued confidence from analysts suggest a stable outlook for the company’s future initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.